Aptamer Details

Back to Search Results

C3 hybrid aptamer with PSMA-617 pharmacophore (from Pluvicto drug) targeting for PSMA (ID# 9652)

Aptamer Chemistry: DNA

Target: Prostate-specific membrane antigen (PSMA)

Antigen/Target Category: Protein

Affinity (Kd): 0.8 nM (reported value)

Binding Conditions/Buffer: Binding buffer: 120 mM NaCl, 5 mM MgCl2, 5 mM KCl, 40 mM HEPES pH 7.4.

Binding Temp: 25°C

Refolding Protocol: Heated at 95°C for 5 min, then cooled to room temperature for 15 min

Comments: Nucleotides of T and C are modified to be phenol-dT and naphthyl-dC. Prior to 5' primer, bait of pharmacophore PSMA-617 from the FDA approved drug "Pluvicto" is attached.

Sequence ():

Length: 79

Molecular Weight: 24668.1 g/mole

Extinction Coefficient: 814100 L/(mole·cm)

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Reference:

Liu, K., Robinson, N., Tekoglu, E., Lozada, J., Yu, I. P. L., Tai, R. A., Ozturan, D., Dikbas, U. M., Lack, N. A., Cox, M. E., Mannas, M. P., Cohen, P., Goldenberg, S. L., & Perrin, D. M. (2025). Baited SELEX: Drug-Directed Selection of Aptamers to PSMA for in vivo targeting of prostate cancer xenografts in mice. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.5c13307

Have your aptamer oligo synthesized ORDER